A biomarker of poor collateral circulation, UBE2L3, and its application
By blocking the binding of UBE2L3 to Parkin using small molecule inhibitors or gene silencing vectors, the problem of imprecise intervention in CTO collateral circulation has been solved, the efficiency of collateral circulation establishment in CTO patients has been improved, precise intervention and diversified treatment of collateral circulation in CTO patients have been achieved, and clinical prognosis has been improved.
Patent Information
- Application Number
- CN202610426839.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-04-01
- Publication Date
- 2026-05-26
Smart Images

Figure CN122081482A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biomedical technology, and in particular to a biomarker of poor collateral circulation, UBE2L3, and its applications. Background Technology
[0002] The prevalence of chronic coronary artery occlusive disease (CAOC) continues to rise, becoming a major public health problem threatening public health. The core pathophysiological basis of this disease is the narrowing or occlusion of the main blood-supplying coronary arteries, leading to ischemia and hypoxia in downstream myocardial tissue, ultimately causing irreversible damage or even death of myocardial cells. Current mainstream treatments, such as thrombolysis, percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG), aim to directly open or reconstruct blood flow in large vessels. However, these methods have significant limitations, including strict time windows, unavoidable reperfusion injury, unsuitability for surgery in some patients due to anatomy or physical condition, and the possibility of restenosis post-surgery. Therefore, there is an urgent need to explore new alternative or adjuvant treatment strategies that can fundamentally improve myocardial perfusion and protect ischemic myocardium.
[0003] Against this backdrop, the body's inherent compensatory vascular network—collateral circulation—has garnered significant clinical attention. When the main blood supply vessel is blocked, pre-existing or newly formed collateral circulation can provide alternative blood flow to the ischemic area. Numerous studies have confirmed that good collateral circulation can effectively limit the extent of myocardial infarction, maintain cardiac function, reduce the incidence of major adverse cardiovascular events, and significantly improve patients' long-term prognosis and quality of life. Based on this compensatory mechanism, the "therapeutic angiogenesis" strategy has emerged, with the core objective of reconstructing blood flow pathways in ischemic tissue by promoting angiogenesis or accelerating the maturation of existing microvascular networks. The current mainstream approach is to deliver pro-angiogenic factors (such as vascular endothelial growth factor VEGF and fibroblast growth factor FGF) to the ischemic site. However, the clinical translation of this strategy faces severe challenges: exogenous growth factors have short half-lives, requiring repeated high-dose administration, and are prone to off-target effects such as tissue edema, abnormal angiogenesis, and even promoting tumor growth, leading to unstable efficacy and potential safety risks.
[0004] Angiogenesis is a complex, energy-dependent biological process involving the activation, proliferation, migration, and lumen formation of vascular endothelial cells. These cellular behaviors all require stable mitochondrial function and a sufficient supply of energy (ATP). Mitophagy is a core mechanism for maintaining intracellular mitochondrial homeostasis, selectively clearing impaired mitochondria to ensure cellular homeostasis. However, under stress conditions such as persistent ischemia and hypoxia, mitophagy may be overactivated, leading to massive mitochondrial clearance, severe ATP deficiency, and excessive accumulation of reactive oxygen species, which in turn can cause endothelial cell dysfunction or even apoptosis, ultimately impairing their angiogenic capacity. Studies have shown that Parkin-mediated mitophagy is one of the most important pathways regulating mitochondrial clearance under ischemic conditions. When the mitochondrial membrane potential decreases, Parkin is specifically recruited to the outer mitochondrial membrane and ubiquitinates outer membrane proteins through its E3 ubiquitin ligase activity, thereby recruiting autophagy adaptor proteins (such as p62) to initiate autophagosome encapsulation and lysosomal degradation. However, persistent or overactivated Parkin pathways are considered a key factor exacerbating the energy metabolism crisis in endothelial cells and hindering angiogenesis and collateral circulation formation.
[0005] Ubiquitination of proteins is a crucial post-translational modification that finely regulates angiogenesis-related signaling pathways (such as the VEGF / VEGFR-2 and PI3K / Akt pathways). The ubiquitination process is catalyzed sequentially by E1 activators, E2 conjugators, and E3 ligases. Among these, E2 ubiquitin conjugators play a decisive role in determining ubiquitin chain type and modification specificity. UBE2L3 is an important E2 ubiquitin conjugator. Recent research has found that UBE2L3 can specifically bind to the RING domain at the C-terminus of the Parkin protein, efficiently delivering activated ubiquitin molecules to the Parkin catalytic center, thereby significantly enhancing Parkin's E3 ligase activity, amplifying ubiquitination signals in mitochondrial outer membrane proteins, and strongly promoting mitophagy. In a myocardial ischemia-reperfusion injury model, Parkin-mediated excessive mitophagy impairs endothelial cell metabolism, promotes apoptosis, and inhibits angiogenesis in the later stages of ischemia. Preliminary studies suggest that inhibiting UBE2L3 expression can reduce the recruitment of Parkin and p62 to mitochondria, thereby alleviating excessive mitophagy. It is worth noting that although UBE2L3 has been studied in fields such as autoimmune diseases and tumors, its specific target, regulatory network and integration mechanism in the complex pathophysiological process of collateral circulation formation are still unclear. Summary of the Invention
[0006] The purpose of this invention is to provide a collateral circulation insufficiency biomarker UBE2L3 and its application, in order to solve the technical problems in the prior art of inaccurate target points for CTO collateral circulation intervention, unstable efficacy, and inability to predict the collateral circulation function of patients through UBE2L3 index, thereby achieving the goal of improving the efficiency of collateral circulation establishment in CTO patients and improving clinical prognosis.
[0007] To achieve the above-mentioned objectives, the present invention provides the following technical solution: This invention provides a biomarker for poor collateral circulation, UBE2L3.
[0008] Preferably, the collateral circulation impairment biomarker UBE2L3 is expressed at elevated levels in patients with collateral circulation impairment.
[0009] Preferably, the overexpression of UBE2L3 can inhibit the proliferation and migration of vascular endothelial cells and inhibit angiogenesis.
[0010] The present invention also provides the application of the above-mentioned collateral circulation failure biomarker UBE2L3 in the preparation of products for treating and promoting collateral circulation formation.
[0011] The present invention also provides a product that promotes the establishment of collateral circulation, the product comprising a UBE2L3 small molecule inhibitor and a gene silencing vector.
[0012] Preferably, the application method of the product that promotes the establishment of collateral circulation includes local targeted delivery, wherein the local targeted delivery is performed by intracoronary injection or intramyocardial injection via the endocardium, directly delivering the gene silencing vector or UBE2L3 small molecule inhibitor to the CTO lesion area and its downstream myocardium.
[0013] Mechanism of action: After the formulation is taken up by vascular endothelial cells and cardiomyocytes, shUBE2L3 is expressed and the intracellular UBE2L3 gene is silenced, or small molecule inhibitors directly inhibit the activity of UBE2L3 protein. This blocks the binding of UBE2L3 to Parkin and the degradation of Drp1, restores endothelial cell function, promotes the formation of new blood vessels, and thus improves blood perfusion in ischemic areas.
[0014] The present invention also provides an application of the above-mentioned collateral circulation failure biomarker UBE2L3 in the preparation of products for detecting collateral circulation formation.
[0015] The present invention also provides a product for detecting the formation of collateral circulation, the product comprising a UBE2L3 gene detection kit, a UBE2L3 gene detection chip, or a UBE2L3 protein detection kit.
[0016] Preferably, the gene detection kit includes primer pairs that specifically amplify the UBE2L3 gene, and the protein detection kit contains monoclonal or polyclonal antibodies that specifically bind to the UBE2L3 protein.
[0017] The beneficial effects of this invention compared to the prior art are as follows: (1) This invention clarifies for the first time the key role of UBE2L3 in inhibiting the formation of collateral circulation in chronic total coronary artery occlusion (CTO), and establishes the "UBE2L3-Parkin-Drpl" axis as a key endogenous inhibitory pathway for regulating CTO collateral circulation. This provides a clear and well-defined intervention target for developing novel precision therapies that promote therapeutic angiogenesis, and solves the problems of unstable efficacy and off-target risks caused by the broad target range of current angiogenesis strategies.
[0018] (2) This invention overcomes the limitations of existing technologies that rely on imaging techniques such as coronary angiography and Rentrop grading for subjective and morphological assessment. By quantitatively detecting the plasma soluble molecular marker UBE2L3, it provides a minimally invasive and objective assessment method that can identify patients with chronic coronary artery total occlusion and low potential for collateral circulation earlier and more accurately. This invention also demonstrates that UBE2L3 is an independent influencing factor for collateral circulation formation. Its level detection helps to stratify the patient's self-compensation capacity for risk before formulating a revascularization strategy, thereby guiding clinicians to plan proactive interventions for high-risk patients in advance (such as prioritizing revascularization or combining angiogenesis therapy), and achieving individualized treatment decisions.
[0019] (3) This invention provides a flexible and efficient intervention strategy based on the UBE2L3 target, enabling the development of diverse treatment methods. It can develop gene therapy agents (such as AAV vectors that target and silence UBE2L3 to achieve long-term regulation) and small molecule inhibitors (for easy administration), providing diversified solutions for different clinical needs. Furthermore, for patients who cannot tolerate or are unsuitable for traditional revascularization treatments such as percutaneous coronary intervention or coronary artery bypass grafting, targeting and inhibiting UBE2L3 provides a novel non-surgical biological therapy strategy aimed at enhancing endogenous angiogenesis, potentially fundamentally improving myocardial ischemia and reducing the risk of long-term adverse events such as myocardial infarction and heart failure.
[0020] (4) The diagnostic products of this invention are easy to develop. Based on mature immunoassay and other immunoassay technologies, UBE2L3 kits for clinical testing can be developed rapidly, facilitating their promotion and application in medical institutions and enabling rapid detection. This invention also reveals a clear molecular target (UBE2L3) and its interaction mechanism with Parkin, providing a clear target and validation pathway for high-throughput screening of UBE2L3 small molecule inhibitors or protein-protein interaction inhibitors, which will significantly accelerate the research and development of novel pro-angiogenic drugs. Attached Figure Description
[0021] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0022] Figure 1 This is an example of UBE2L3 expression in patients with chronic coronary occlusive disease in Example 1 of the present invention; Figure 2 In Example 3 of this invention, knocking down UBE2L3 in human umbilical vein endothelial cells (HUVEC) promotes endothelial cell proliferation. Figure 3 In Example 3 of this invention, knocking down UBE2L3 in human umbilical vein endothelial cells (HUVEC) promotes endothelial cell migration. Figure 4 In Example 3 of this invention, knocking down UBE2L3 in human umbilical vein endothelial cells (HUVEC) promotes endothelial cell invasion and tube formation ability. A represents the Transwell assay result, and B represents the tube formation experiment result. Detailed Implementation
[0023] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0024] It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the invention. Furthermore, with respect to numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Every smaller range between any stated value or intermediate value within a stated range, and any other stated value or intermediate value within said range, is also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.
[0025] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.
[0026] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be apparent to those skilled in the art. This specification and embodiments are merely exemplary.
[0027] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.
[0028] Example 1 Example 1 of this invention detected the differential expression of UBE2L3 in collateral circulation formation in CTO patients. The specific steps are as follows: Patients with a confirmed diagnosis of CTO via coronary angiography were selected. The coronary angiography results were reviewed by senior attending physicians or associate chief physicians with extensive experience in coronary intervention at the Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University. The presence and severity of collateral circulation were assessed and graded. In case of disagreement between the two physicians, a third person (the attending physician) made the final judgment. Based on the Rentrop grading system, all patients were divided into a poor collateral circulation group (Rentrop grade 0-1) and a good collateral circulation group (Rentrop grade 2-3). Serum samples were collected before recanalization, and the expression level of UBE2L3 was measured using a double-antibody sandwich ELISA method. The results are as follows: Figure 1 As shown.
[0029] Figure 1 The results showed that the expression level of UBE2L3 in the poor collateral circulation group was significantly higher than that in the good collateral circulation group, and the level was the highest in Rentrop 0 CTO patients. Therefore, UBE2L3 can be used as a biomarker to predict the establishment of collateral circulation in patients with chronic coronary occlusive disease.
[0030] Example 2 Example 2 of this invention investigated the effect of plasma UBE2L3 expression levels on collateral circulation formation in CTO patients. The specific steps are as follows: All clinical indicators in Table 1 that may be related to the formation of collateral circulation were included in the univariate logistic regression analysis, and the results are shown in Tables 1 and 2.
[0031] Table 1. Comparison of baseline characteristics between CTO patients with good and poor collateral circulation.
[0032] Note: BMI: Body Mass Index; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin II receptor antagonist; ARNI: Angiotensin receptor neprilysin inhibitor; VEGFA: Vascular endothelial growth factor A; UBE2L3: Ubiquitin-coupled enzyme E2L3. *: Expressed as M(Q1, Q3). 1 mmHg = 0.133 kPa.
[0033] Table 2. Multivariate Logistic Regression Analysis of Poor Collateral Circulation Formation in CTO Patients (n=489)
[0034] Note: UBE2L3: ubiquitin-coupled enzyme E2L3; BMI: body mass index; LDL-C: low-density lipoprotein cholesterol; VEGFA: vascular endothelial growth factor A. 1 mmHg = 0.133 kPa. *: UBE2L3 level > 2.907 ng / ml, refer to ≤ 2.907 ng / ml; VEGFA level > 283.631 pg / ml, refer to ≤ 283.631 pg / ml.
[0035] Univariate logistic regression analysis showed that a history of diabetes, a history of hypertension, fasting blood glucose, systolic blood pressure, diastolic blood pressure, BMI, plasma VEGFA level ≤283.631 pg / ml, and plasma UBE2L3 level >2.907 ng / ml were all associated with poor collateral circulation formation (all P < 0.05).
[0036] Further collinearity diagnosis was performed on the variables that were statistically significant in the univariate analysis. The following factors were included in the multivariate logistic regression model: history of diabetes, diastolic blood pressure level, BMI, plasma VEGFA level >283.631 pg / ml, plasma UBE2L3 level >2.907 ng / ml, and factors that may be associated with poor collateral circulation formation, such as smoking history, drinking history, gender, age, LDC-C, and number of diseased branches (≥2). After adjusting for confounding factors, elevated plasma UBE2L3 levels (OR=1.581, 95%CI: 1.032–2.422, P=0.035), elevated BMI levels (OR=1.069, 95%CI: 1.007–1.135, P=0.028), elevated diastolic blood pressure (OR=1.031, 95%CI: 1.012–1.050, P=0.001), and a history of diabetes (OR=1.885, 95%CI: 1.192–2.981, P=0.007) were all independent risk factors for poor coronary collateral circulation.
[0037] Example 3 Example 3 of this invention conducted an experiment on the effects of UBE2L3 on VEGFA-induced cell proliferation, migration, and tube formation. The specific steps are as follows: 1. Experimental Materials and Grouping Human umbilical vein endothelial cells (HUVECs) were selected as the research subject, and the experiment was divided into four groups to verify the function of the UBE2L3 gene: Con group (control group): HUVECs in the logarithmic growth phase were seeded into cell culture dishes and cultured routinely in a 37°C, 5% CO2 incubator. VEGFA group: When the confluence of conventionally cultured cells reaches 50%-60%, 10 ng / mL VEGFA cytokine is added to induce cell phenotypic transformation; UBE2L3-KD+VEGFA group: When the confluence of conventionally cultured cells reached 40%-50%, UBE2L3-KD recombinant virus solution (pADV-U6-shRNA(UBE2L3)-CMV-EGFP) was added. The virus dosage was adjusted according to an MOI of 200. A blank control virus group was also set up. After infection, the cells were incubated in a constant temperature incubator for 48 hours. The fluorescence expression of the cells was observed and recorded under a fluorescence microscope. The viral infection efficiency was confirmed to be ≥ the preset threshold (80%) by statistically analyzing the proportion of fluorescently positive cells to the total number of cells (or by quantitative analysis of fluorescence intensity), ensuring that the UBE2L3 knockdown effect was achieved. Only cells with the required infection efficiency were selected for subsequent treatment. Then, 10 ng / mL of VEGFA cytokine was added to induce cell phenotypic transformation. UBE2L3-OE+VEGFA group: When the confluence of conventionally cultured cells reached 40%-50%, UBE2L3-OE recombinant virus solution (pcADV-EF1-mNeonGreen-CMV-MCS-3×FLAG) was added. The virus dosage was adjusted according to an MOI of 200. A blank control virus group was also set up. After infection, the cells were incubated in a constant temperature incubator for 48 hours. The fluorescence expression of the cells was observed and recorded under a fluorescence microscope. The virus infection efficiency was confirmed to be ≥ the preset threshold (80%) by statistically analyzing the proportion of fluorescent positive cells to the total number of cells (or by quantitative analysis of fluorescence intensity), ensuring that the UBE2L3 overexpression effect met the target. Only cells with the required infection efficiency were selected for subsequent treatment. Then, 10 ng / mL VEGFA cytokine was added to induce cell phenotypic transformation.
[0038] 2. Experimental materials: (1) The recombinant viral sequence of UBE2L3-KD (pADV-U6-shRNA(UBE2L3)-CMV-EGFP) is as follows: 1) shRNA identifier and target sequence: The target sequence (TargetSeq) of the shRNA used is shown below: SEQ ID NO.1: CCACCGAAGATCACATTTAAA; 2) Viral vector insertion frame: The insertion sequence frame of this shRNA in the viral vector is as follows: Forward insertion sequence (F-SEQ ID NO.2): CgggCCACCGAAGATCACATTTAAACTCGAGTTTAAATGTCATCTTCGGTGGTTTTTTg; Reverse insertion sequence (R-SEQ ID NO.3): aattcaaaaaaCCACCGAAGATCACATTTAAACTCGAGTTTAAATGTCATCTTCGGTGG; (Note: The frame includes the 5' "Cggg" element, the STEM region (shRNA target sequence and its complementary sequence), the Loop region "CTCGAG", and the 3' "TTTTTTg" termination element.)
[0039] (2) Negative control virus group, targeting non-specific sequence (SEQ ID NO.4): TTCTCCGAACGTGTCACGT.
[0040] (3) The recombinant viral fluid sequence of UBE2L3-OE (pcADV-EF1-mNeonGreen-CMV-MCS-3×FLAG) is as follows: Forward sequencing primers (SEQ ID NO.5): CMV-F CGCAAATGGGCGGTAGGCGTG; Reverse sequencing primers (SEQ ID NO.6): SV40-pArev GAAATTTGGTGATGCTATTGC; (4) Transwell: Transwell chamber, serum-free DMEM / F12 medium, 4% paraformaldehyde fixative, 0.1% crystal violet staining solution (containing 20% methanol), phosphate buffer (PBS, pH 7.4) (5) HUVEC tube formation assay (detection of angiogenesis ability): Matrigel (brand: Corning, -20℃ frozen, thawed overnight at 4℃ before use), serum-free DMEM / F12 medium, DMEM / F12 medium containing 2% FBS; 3. Experimental methods and procedures (1) Cell proliferation capacity detection (EdU staining method) Cell seeding and infection: Logarithmically growing HUVECs were seeded into cell culture dishes and cultured routinely in a 37°C, 5% CO2 incubator. When the confluence of the routinely cultured cells reached 40%-50%, the corresponding recombinant virus solution was added, and the virus dosage was adjusted according to an MOI of 200. A blank control virus group was also set up. After infection, the cells were incubated in an incubator for another 48 hours, and the fluorescence expression of the cells was observed and recorded under a fluorescence microscope. The virus infection efficiency was confirmed to be ≥ the preset threshold (80%) by statistically analyzing the proportion of fluorescently positive cells to the total number of cells (or by quantitative analysis of fluorescence intensity), ensuring that the UBE2L3 knockdown or overexpression effect was achieved. Only cells with the required infection efficiency were selected for subsequent treatment.
[0041] Starvation and induction: 24 h after transfection, cells were starved for 12 h in serum-free medium to synchronize them, and then 10 ng / mL VEGFA was added for induction for 24 h.
[0042] Labeling and staining: Incubate with EdU reaction solution for 2 hours. After cell fixation, use Apollo staining solution to label proliferating cells as red, and use DAPI to label all cell nuclei as blue.
[0043] Imaging: Images were taken under a fluorescence microscope, and the percentage of EdU-positive cells in the total cell count was calculated. The results are as follows: Figure 2 As shown.
[0044] Figure 2The results showed that UBE2L3-KD enhanced migration, and the scratch healing rate was highest in the UBE2L3-KD group after 12 hours of induction. UBE2L3-OE blocked migration, and the migration ability of the UBE2L3-OE+VEGFA group was significantly inhibited compared with the VEGFA alone group.
[0045] (2) Cell migration ability detection (scratch test) Scratch preparation: After the cells have grown to 100% confluence, use a 200μL pipette tip to scribble vertical lines on the bottom of the plate.
[0046] Observation after drug administration: After washing, add culture medium containing 1% FBS and 10 ng / mL VEGFA.
[0047] Time point recording: Changes in scratch spacing were recorded at 0h, 6h, and 12h to observe cell migration towards the scratch area. Results are as follows: Figure 3 As shown.
[0048] Figure 3 The results showed that UBE2L3-KD enhanced migration, and the scratch healing rate was highest in the UBE2L3-KD group after 12 hours of induction. UBE2L3-OE blocked migration, and the migration ability of the UBE2L3-OE+VEGFA group was significantly inhibited compared with the VEGFA alone group.
[0049] (3) Transwell 1) Cell pretreatment: The four groups of treated HUVECs (Con group, VEGFA group, UBE2L3-KD+VEGFA group, and UBE2L3-OE+VEGFA group) were washed twice with serum-free DMEM / F12 medium, then resuspended in serum-free medium, and the cell density was adjusted to 5×10⁶ cells / year. 4 pcs / mL (this density was determined through preliminary experiments).
[0050] 2) Transwell preparation: Place the Transwell chamber in a 24-well plate and add 600 μL of DMEM / F12 medium containing 10% FBS (as a chemokine) to the lower chamber, avoiding the formation of air bubbles.
[0051] 3) Cell seeding: Add 200 μL of the above cell suspension to the upper chamber of the small chamber, and set up 3 biological replicates for each group; place the 24-well plate in a 37℃, 5% CO2 constant temperature incubator for 24 h.
[0052] 4) Fixation and staining: After incubation, remove the Transwell chamber, discard the liquid in the upper chamber, and wash twice with PBS; add 4% paraformaldehyde fixative and fix at room temperature for 20 min; discard the fixative, wash with PBS, add 0.1% crystal violet staining solution, and stain at room temperature for 15 min.
[0053] 5) Background removal: Gently wipe away unmigrated cells from the upper chamber membrane surface with a cotton swab, and then wash three times with PBS to remove residual staining solution.
[0054] 6) Statistical analysis of results Under an optical microscope (model: Olympus CX43), five fields of view (100× magnification) were randomly selected from each group to count the number of cells that migrated to the surface of the lower chamber membrane. The average number of cells in three replicates for each group was calculated as an indicator of the migration ability of HUVECs in that group. The results are as follows: Figure 4 As shown in Figure A.
[0055] (4) Tube forming experiment 1) Matrigel plating: The entire process was performed on ice. Matrigel was diluted with pre-cooled serum-free DMEM / F12 medium at a volume ratio of 1:1. 50 μL of diluted Matrigel was added to each well of the 96-well plate. The 96-well plate was placed in a 37°C, 5% CO2 incubator for 30 min to allow the Matrigel to solidify completely.
[0056] 2) Cell pretreatment: The four groups of treated HUVECs were resuspended in DMEM / F12 medium containing 2% FBS and the cell density was adjusted to 2×10⁴ cells / year. 4 One hole / hole.
[0057] 3) Cell seeding: Add 100 μL of the above cell suspension to the solidified matrix gel wells, and set up 3 biological replicates for each group; place the 96-well plate in an incubator and incubate for 6 h (this time has been optimized by preliminary experiments and obvious tubular structures can be observed).
[0058] 4) Statistical analysis of results The formation of tubules in each group was observed and photographed (100× magnification) under an inverted microscope (model: Leica DMi1). ImageJ software was used to analyze the images, and two indicators were statistically analyzed: total tubule length and number of branch points. The average value of three replicates was calculated as an indicator of the angiogenesis capacity of the HUVECs in that group. The results are as follows: Figure 4 As shown in B.
[0059] Figure 4 The results showed that, compared with the control group, UBE2L3-KD with the addition of VEGFA significantly promoted the cell invasion and tube formation abilities; while overexpression of UBE2L3 significantly inhibited the cell invasion and tube formation abilities.
[0060] As shown above, knocking down UBE3L3 effectively enhances the migration, proliferation, invasion, and tube formation capabilities of HUVECs induced by VEGFA. Overexpression of UBE2L3, however, significantly inhibits this effect.
[0061] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. A biomarker for poor collateral circulation, UBE2L3.
2. The collateral circulation impairment biomarker UBE2L3 according to claim 1, characterized in that, The biomarker UBE2L3, which describes poor collateral circulation, is expressed at elevated levels in patients with poor collateral circulation.
3. The collateral circulation impairment biomarker UBE2L3 according to claim 1 or 2, characterized in that, The overexpression of UBE2L3 can inhibit the proliferation and migration of vascular endothelial cells and suppress angiogenesis.
4. The use of the collateral circulation impairment biomarker UBE2L3 as described in any one of claims 1 to 3 in the preparation of a product for treating and promoting collateral circulation formation.
5. A product that promotes the establishment of collateral circulation, characterized in that, The products include UBE2L3 small molecule inhibitors and gene silencing vectors.
6. The use of the collateral circulation failure biomarker UBE2L3 as described in any one of claims 1 to 3 in the preparation of products for detecting collateral circulation formation.
7. A product for detecting the formation of collateral circulation, characterized in that, The products include UBE2L3 gene detection kits, UBE2L3 gene detection chips, or UBE2L3 protein detection kits.
8. The product for detecting the formation of collateral circulation according to claim 7, characterized in that, The gene detection kit includes primer pairs that specifically amplify the UBE2L3 gene, and the protein detection kit contains monoclonal or polyclonal antibodies that specifically bind to the UBE2L3 protein.
